Moderna has agreed to a settlement of up to $2.25 billion to resolve a patent infringement lawsuit related to its drug delivery technology, brought forth by Genevant and Arbutus. This settlement comes just days before a jury trial was scheduled to commence, highlighting the urgency and significance of the legal dispute.
The lawsuit centered around key technologies that are integral to Moderna’s mRNA vaccine platform, which has been pivotal in the fight against COVID-19. The resolution of this case not only alleviates potential disruptions to Moderna’s operations but also underscores the competitive landscape within the biopharmaceutical sector, where intellectual property rights are fiercely contested.
For industry stakeholders, this settlement may signal a shift in how companies approach patent litigation, particularly in the rapidly evolving field of mRNA technology. As the market continues to expand, the implications of such legal battles could influence strategic decisions in research and development, partnerships, and overall portfolio management.
Use the database as your supply chain compass →
